GABAergic influences on plus-maze behaviour in mice

Psychopharmacology

Volumn 128, Issue 4, 1996, Pages 380-397

  Dalvi, A ^a   Rodgers, R J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

(+)bicuculline; anxiety; CGP 35348; diazepam; GABA; mice; muscimol; No 711; picr otoxin; plus maze; R(+)baclofen; risk assessment; valproate

Indexed keywords

1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE INHIBITOR; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; BICUCULLINE; DIAZEPAM; GABA UPTAKE INHIBITOR; GABAERGIC RECEPTOR AFFECTING AGENT; MUSCIMOL; PICROTOXIN; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR; CONTROLLED STUDY; ETHOLOGY; GABAERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; BACLOFEN; BEHAVIOR, ANIMAL; BICUCULLINE; DIAZEPAM; GABA MODULATORS; MALE; MICE; MICE, INBRED DBA; MUSCIMOL; NIPECOTIC ACIDS; OXIMES; PICROTOXIN; VALPROIC ACID;

EID: 0029853759     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050148     Document Type: Article

References (80)

1. Ågmo A, Pruneda R, Guzman M, Gutierrez M (1991) GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. Naunyn-Schmiedeberg's Arch Pharmacol 344:314 322
2. Andrews N, File SE (1993) Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 235:109 112
3. Balfour JA, Bryson HM (1995) Valproic acid: a review of its pharmacology and therapeutic potential in indications other than epilepsy. CNS Drugs 2:144 173
4. Barros HMT, Tannhauser SL, Tannhauser MAL, Tannhauser M (1992) Effect of sodium valproate on the open-field behavior of rats. Brazil J Med Biol Res 25:281 287
5. B receptors in mammalian function. Wiley, Chichester, pp 47 60
6. Blanchard DC, Blanchard RJ, Tom P, Rodgers RJ (1990) Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology 101:511 518
7. Blanchard RJ, Blanchard DC (1989) Antipredator defensive behaviors in a visible burrow system. J Comp Psychol 103:70 82
8. Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C (1994) Tiagabine, SK & F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol [Mol Pharmacol Section] 269: 219 224
9. Borden LA, Smith KE, Vaysse PJ-J, Gustafson EL, Weinshank RL, Branchek TA (1995) Re-evaluation of GABA transport in neuronal and glial cell cultures: correlation of pharmacology and mRNA localization. Receptors and Channels 3:129 146
10. Cannizzaro G, Flugy A, Novara V, Provenzano PM (1987) Interaction between naloxone, chlordiazepoxide and valproic acid evaluated by emotional operant behavior in the rat. Arzneimittelforschung 37:6-9
11. Cole JC, Rodgers RJ (1993) An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16 6028) in the murine elevated plus-maze. Behav Pharmacol 4:573 580
12. Cole JC, Rodgers RJ (1994) An ethological analysis of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 114:288 296
13. Cole JC, Rodgers RJ (1995) Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze. Pharmacol Biochem Behav 52:473 478
14. Cook L, Sepinwall J (1980) Benzodiazepine receptor dynamics and ligands. Psychopharmacol Bull 16:30 32
15. Corbett R, Fielding S, Cornfelt M, Dunn RW (1991) GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus-maze procedures. Psychopharmacology 104: 312 316
16. Corda MG, Biggio G (1986) Proconflict effect of GABA receptor complex antagonists reversal by diazepam. Neuropharmacology 25:541 544
17. Costa E, Ferrari P, Ferrero, P, Guidotti A (1984) Multiple signals in GABAergic transmission: pharmacological consequences. Neuropharmacology 23:989 991
18. Cruz APM, Frei F, Graeff FG (1994) Ethopharmacological analysis of behavior on the elevated plus-maze. Pharmacol Biochem Behav 49:171 176
19. de Angelis L (1992) Comparative effects of valproate, anxiolytic, or anxiogenic drugs on the light/dark aversion test. Drug Dev Res 25:331 338
20. De Vry J, Benz U, Schreiber R, Traber J (1993) Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs. Eur J Pharmacol 249:331 339
21. Fernandes C, File SE (1996) The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav 54:31 40
22. File SE (1992) Behavioural detection of anxiolytic action. In: Elliot JM, Heal DJ, Marsden CA (eds) Experimental approaches to anxiety and depression. Wiley, Chichester, pp 25 44
23. File SE, Aranko K (1988) Sodium valproate and chlordiazepoxide in the elevated plus-maze test of anxiety in the rat. Neuropsychobiology 20:82 86
24. File SE, Lister RG (1984) Do the reductions in social interaction produced by picrotoxin and pentylenetetrazole indicate anxiogenic actions? Neuropharmacology 23:793 796
25. Freund RK, Marley RJ, Wehner M (1987) Differential sensitivity to bieuculline in three inbred mouse strains. Brain Res Bull 18: 657 662
26. B antagonists. J Med Chem 38:3313 3331
27. Gardner CR, Piper, DC (1982) Effects of agents which enhance GABA-mediated neurotransmission on licking conflict in rats and exploration in mice. Eur J Pharmacol 83:25 33
28. Giusti A, Guidotti A, Danysz W, Auta J, Costa E (1990) Neuropharmacological evidence for an interaction between the GABA uptake inhibitor CI-966 and anxiolytic benzodiazepines. Drug Dev Res 21:217 225
29. Griebel G, Blanchard DC, Jung A, Blanchard RJ (1995) A model of "antipredator" defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrisic activities. Behav Pharmacol 6:732 745
30. Handley SL, Mithani S (1984) Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 327:1 5
31. Hodges H, Green S (1984) Evidence for the involvement of brain GABA and serotonin systems in the anticonflict effects of ehlordiazepoxide in rats. Behav Neural Biol 40:127 154
32. Hodges H, Green S, Crewes H, Mathers I (1981) Effects of chronic chlordiazepoxide treatment on novel and familiar food preference in rats. Psychopharmacology 75:305 310
33. B ligands on alcohol withdrawal in mice. Pharmacol Bioehem Behav 49:561 566
34. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology 124: 355 364
35. Kerr DIB, Ong J (1992) GABA agonists and antagonists. Med Res Rev 12:593 636
36. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92: 180 185
37. Löscher W (1993) Effects of the antiepileptic drug valproate on metabolism and the function of inhibitory and exitatory amino acids in the brain. Neuroehem Res 18:485 502
38. McCreary AC, McBlane JW, Spooner HA, Handley SL (1996) 5HT systems and anxiety: multiple mechanisms in the elevated X-maze. Pol J Pharmacol 48:1 12
39. Molewijk HE, van der Poel AM, Olivier B (1995) The ambivalent behaviour "stretched attend posture" in the rat as a paradigm to characterize anxiolytic drugs. Psychopharmacology 121: 81 90
40. Nastiti K, Benton D, Brain PE (1991) The effects of compounds acting at the benzodiazepine receptor complex on the ultrasonic calling of mouse pups. Behav Pharmacol 2:121 128
41. Nurnberger JI, Berrettini WH, Simmons-Alling S, Guroff JJ, Gershon ES (1986) Intravenous GABA administration is anxiogenic in man. Psychiatry Res 19:113 117
42. Olsen RW, Ban M, Miller T (1976) Studies on the neuropharmacological activity of bicuculline and related compounds. Brain Res 102:283 299
43. Paredcs RG, Ågmo A (1992) GABA and behavior: the role of receptor subtypes. Neurosci Biobehav Rev 16:145 170
44. B antagonist CGP 35348 inhibits the effects of baclofen on sexual behavior and motor coordination. Brain Res Bull 36:495 497
45. Prado de Carvalho L, Venault P, Rossier J, Chapouthier, G (1983) Anxiogenic properties of convulsive agents. Soc Neurosci Abstr 9: 128
46. Quartermain D, Stone EA, Charbonneau G (1996) Acute stress disrupts risk assessment behavior in mice. Physiol Behav 59: 937 940
47. Ouintero S, Henney H, Lawson P, Mellanby J, Gray JA (1985) The effects of compounds related to γ-aminobutyrate and benzodiazepine receptors on behavioural responses to anxiogenic stimuli in the rat: punished barpressing. Psychopharmacology 85: 244 251
48. A receptor research. Synapse 21:189 274
49. Rasmussen KJ, Schneider HH, Petersen EN (1981) Sodium valproate exerts anti-conflict activity in rats without any concommitant rise in forebrain GABA levels. Life Sci 29:2163 2170
50. 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br J Pharmacol 116: 2081 2089
51. Rodgers RJ, Cole JC (1993a) Anxiety enhancement in the elevated plus-maze by immediate prior exposure to social stressors. Physiol Behav 53:383-388
52. Rodgers RJ, Cole JC (1993b) Influence of social isolation, gender, strain and prior novelty on plus-maze behaviour in mice. Physiol Behav 54:729-736
53. Rodgers RJ, Cole JC (1994) The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA (eds) Ethology and psychopharmacology. Wiley, Chichester, pp 9 44
54. Rodgers RJ, Dalvi A (1997) Anxiety, defense and the plus-maze. Neurosci Biobehav Rev (in press)
55. Rodgers RJ, Johnson NJT (1995) Factor analysis of spatiotemporal and ethological measures in the marine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 52:297 303
56. Rodgers RJ, Cole JC, Cobain MR, Daly P, Doran PJ, Eells JR, Wallis P (1992) Anxiogenic-like effects of fluprazine and elloprazine in the mouse elevated plus-maze: profile comparisons with 8-OH-DPAT, CGS 12066B, TF-MPP and mCPP. Behav Pharmacol 3:621 634
57. Rodgers RJ, Cole JC, Aboualfa K, Stephenson LH (1995) Ethopharmacological analysis of the effects of putative "anxiogenic" agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52:805 813
58. B receptors in the motor inhibition produced by agonists of brain cannabinoid receptors. Behav Pharmacol 7:299 302
59. Sanger DJ (1985) GABA and the behavioral effects of anxiolytic drugs. Life Sci 36:1503 1513
60. Sayin U, Purali N, Ozkan T, Altung T, Buyukdevrim S (1992) Vigabatrin has an anxiolytic effect in the elevated plus maze-test of anxiety. Pharmacol Biochem Behav 43:529 535
61. Shephard RA (1986) Neurotransmitters, anxiety and benzodiazepines: a behavioral review. Neurosci Biobehav Rev 10: 449 461
62. Shephard RA (1987) Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action. Life Sci 40: 2429 2436
63. Shephard RA, Hamilton MS (1989) Chlordiazepoxide and valproate enhancement of saline drinking by non-deprived rats: effects of bicuculline, picrotoxin and Ro15-1788. Pharmaeol Biochem Behav 33:285 290
64. Shephard RA, Toal L, Leslie JC (1990) Effects of agonists and antagonists at the GABA/benzodiazepine receptor on conditioned suppression in rats. Pharmacol Biochem Behav 36: 39 43
65. Shephard RA, Wedlock P, Wilson NE (1992) Direct evidence for the mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav 41:651 653
66. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology 116:56 64
67. Sherif F, Oreland L (1994) Effects of chronic treatment with the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in rats. Behav Brain Res 63:11 15
68. Sherif F, Harro J, El-hwuegi A, Oreland L (1994) Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory behaviour. Pharmacol Biochem Behav 49:801 805
69. Shimada T, Matsumoto K, Osanal M, Matsuda H, Terasawa K, Watanabe H (1995) The modified light/dark transition test in mice: evaluation of classic and putative anxiolytic and anxiogenic drugs. Gen Pharmacol 26: 205-210
70. Simiand J, Keane PE, Morre M (1984) The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology 84:48 53
71. A receptor subtypes. Pharmacol Rev 47: 181 234
72. Soubrie P, Thiebot M-H, Simon P (1979) Enhanced suppressive effects of aversive events induced in rats by picrotoxin: possibility of a GABA control on behavioral inhibition. Pharmacol Biochem Behav 10:463 469
73. Stutzmann J, Böhme GA, Cochon M, Roux M, Blanchard J (1987) Proconflict and electrocorticographic effects of drugs modulating GABAergic neurotransmission. Psychopharmacology 91: 74 79
74. Suzdak PD, Jansen JA (1995) A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 36:612-626
75. Suzdak PD, Frederiksen K, Andersen KE, Sorensen PO, Knutsen LJS, Nielsen EB (1992) NNC-711, a novel potent and selective gamma-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur J Pharmacol 223: 189 198
76. Toal L, Leslie JC, Shephard RA (1991) Effects of chlordiazepoxide and putative anxiogenics on conditioned suppression in rats. Physiol Behav 49:1085 1090
77. Thiébot MH, Laporte AM, Soubrié P (1987) Microgram doses of diazepam do not induce proconvulsant or proconflict effects in rodents. Psychopharmacology 93: 389-392
78. Treit D (1987) Ro 15-1788, CGS 8216, picrotoxin, and pentylenetetrazol: do they antagonize anxiolytic drug effects through an anxiogenic action? Brain Res Bull 19:401-405
79. Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze test. Pharmacol Biochem Behav 44:463 469
80. Zakusov VV, Ostrovskaya RV, Kozhechkin S.N, Markovic VV, Molodavkin, GM, Voronina TA (1977) Further evidence for GABAergic mechanisms in the action of benzodiazepines. Arch Int Pharmacodyn 229:313 326